DPP4 and chronic myelogenous leukemia, BCR-ABL1 positive: Based on this evidence, also considering that the monitoring of residual LSCs from BM samples is not practical, our group first investigated the presence of CD26+ LSCs in peripheral blood (PB) samples compared to BM samples of Chronic-Phase (CP) CML patients at diagnosis using a flow cytometry assay [51].